Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03953443 · ClinicalTrials.gov registry record
Expression & Epigenetic Silencing of MicroRNA for Predicting Therapeutic Response and Prognosis of HPV-negative HNSCC
A clinical trial, sponsored by New Mexico Cancer Research Alliance.
- Completed
- Registry status
- 25
- Enrollment target
NCT03953443 is a clinical trial that has completed, run by New Mexico Cancer Research Alliance. The registered enrollment target is 25 participants.
The verdict
NCT03953443 has completed, sponsored by New Mexico Cancer Research Alliance.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
A two-part molecular epidemiological study will be conducted to comprehensively assess the association between miR expression and miR promoter methylation and the response to therapy and prognosis in primary, HPV-negative HNSCC patients. Part 1 will be a prospective collection of 25 pairs of fresh tumor-distant normal mucosal tissue in patients with HNSCC. Ultimately, 15 HPV-negative tumor-mucosal pairs will be utilized for discovery work in identifying miRs whose expression is up- or down-regulated in tumors. Part 2 will test the association between miR expression and miR promoter methylation, and therapeutic response and survival in all archived surgical cases of HPV-negative HNSCC at University of New Mexico Hospital (UNMH) collected after 1990.
Interventions
- OTHER Not interventional
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2010-12-17 |
| Est. Completion | 2023-03-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03953443
The ClinicalTrials.gov registry entry for NCT03953443 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New Mexico Cancer Research Alliance, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Not interventional is the first listed.
NCT03953443 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03953443 about?
NCT03953443 is a clinical study titled "Expression & Epigenetic Silencing of MicroRNA for Predicting Therapeutic Response and Prognosis of HPV-negative HNSCC". A two-part molecular epidemiological study will be conducted to comprehensively assess the association between miR expression and miR promoter methylation and the response to therapy and prognosis in primary, HPV-negative HNSCC patients. Part 1 will be a prospective collection of 25 pairs of fresh t...
What is the current status of trial NCT03953443?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2010-12-17. Estimated completion is 2023-03-14.
What interventions are being tested in trial NCT03953443?
The interventions under investigation include: Not interventional (OTHER).
Who is sponsoring clinical trial NCT03953443?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.